A carregar...
Case Report: Favorable Response to the Tyrosine Kinase Inhibitor Apatinib in Recurrent Merkel Cell Carcinoma
BACKGROUND: As angiogenesis is an essential step in tumor growth and metastasis, the tyrosine kinase inhibitor (TKI) apatinib has become a revolutionary anticancer therapy across various malignancies. However, its efficiency and safety in Merkel cell carcinoma (MCC) are uncertain. CASE PRESENTATION:...
Na minha lista:
| Publicado no: | Front Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7966513/ https://ncbi.nlm.nih.gov/pubmed/33747940 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.625360 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|